Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment
19 mars 2024 10h00 HE
|
Gynesonics
Gynesonics announces key executive appointments to further accelerate and expand adoption of the Sonata Treatment.
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
02 janv. 2024 11h13 HE
|
Gynesonics
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
02 nov. 2023 09h41 HE
|
Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
CORRECTION – Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
01 nov. 2023 20h08 HE
|
Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
01 nov. 2023 16h00 HE
|
Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
25 oct. 2023 16h07 HE
|
Gynesonics
Gynesonics is pleased to announce that its Sonata Procedure has been used to treat over 1,000 women in the United States in 2023
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
17 oct. 2023 12h00 HE
|
Gynesonics
Gynesonics' Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids is Now Covered by UnitedHealthcare
01 août 2023 15h02 HE
|
Gynesonics
REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is...
Gynesonics Names Industry Veteran Skip Baldino President and CEO, Announces $25M Financing to Expand Worldwide Commercialization
11 avr. 2023 12h00 HE
|
Gynesonics
REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,...